Paradigm Capital Management Inc. NY Has $435,000 Holdings in Standard BioTools Inc. (NASDAQ:LAB)

Paradigm Capital Management Inc. NY decreased its stake in Standard BioTools Inc. (NASDAQ:LAB) by 54.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 248,400 shares of the company’s stock after selling 301,600 shares during the period. Paradigm Capital Management Inc. NY owned approximately 0.07% of Standard BioTools worth $435,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of LAB. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Standard BioTools by 4.5% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 168,777 shares of the company’s stock worth $295,000 after purchasing an additional 7,304 shares during the period. JPMorgan Chase & Co. raised its holdings in Standard BioTools by 7.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 139,748 shares of the company’s stock valued at $270,000 after acquiring an additional 9,995 shares in the last quarter. HighTower Advisors LLC lifted its position in shares of Standard BioTools by 13.0% in the 4th quarter. HighTower Advisors LLC now owns 92,791 shares of the company’s stock worth $162,000 after acquiring an additional 10,690 shares during the period. Invesco Ltd. grew its holdings in shares of Standard BioTools by 7.5% during the 4th quarter. Invesco Ltd. now owns 175,041 shares of the company’s stock worth $306,000 after purchasing an additional 12,194 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD increased its position in shares of Standard BioTools by 10.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 181,468 shares of the company’s stock valued at $318,000 after purchasing an additional 16,475 shares during the period. Institutional investors own 53.74% of the company’s stock.

Standard BioTools Price Performance

Standard BioTools stock opened at $1.05 on Tuesday. The business has a 50 day simple moving average of $1.13 and a 200 day simple moving average of $1.48. The company has a market capitalization of $398.81 million, a PE ratio of -1.48 and a beta of 1.80. Standard BioTools Inc. has a one year low of $0.95 and a one year high of $2.74.

Insider Buying and Selling at Standard BioTools

In other Standard BioTools news, Director Casdin Partners Master Fund, L acquired 4,820,959 shares of the business’s stock in a transaction on Friday, February 28th. The stock was purchased at an average price of $1.06 per share, for a total transaction of $5,110,216.54. Following the transaction, the director now owns 58,846,780 shares in the company, valued at $62,377,586.80. This trade represents a 8.92% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 23.16% of the company’s stock.

Analyst Ratings Changes

Separately, KeyCorp downgraded shares of Standard BioTools from an “overweight” rating to a “sector weight” rating in a research note on Thursday, February 27th.

Standard BioTools Company Profile

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.